Home > Insider Trading > Filing (0001104659-16-131384)

Filing Details

Accession Number:: 0001104659-16-131384
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-07-06 21:22:46
Reporting Period:: 2016-07-06

Filing Date:: 2016-07-06
Accepted Time:: 2016-07-06 21:22:46
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1556263	Syros Pharmaceuticals Inc.	SYRS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1219042	Robert Nelsen	C/O Arch Venture Partners 8755 West Higgins Road, Suite 1025 Chicago IL 60631		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-07-06	266,666	$0.00	479,999	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-07-06	1,333,333	$0.00	1,813,332	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-07-06	2,000,000	$0.00	3,813,332	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-07-06	423,805	$0.00	4,237,137	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-07-06	400,000	$12.50	4,637,137	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2016-07-06	1,000,000	$0.00	266,666	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2016-07-06	5,000,000	$0.00	1,333,333	$0.00
Common Stock	Series A-3 Preferred Stock	Disposition	2016-07-06	7,500,000	$0.00	2,000,000	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-07-06	1,589,269	$0.00	423,805	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The Series A-1 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series A-2 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series A-3 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-3 Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
These shares are owned directly by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"). The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"). The Managing Directors of ARCH VII LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by ARCH Fund VII. Each Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of such securities for Section 16 or any other purpose.